You just read:

Robbins Geller Rudman & Dowd LLP Updates Investors Regarding Securities Class Action Suit Against Keryx Biopharmaceuticals, Inc. And Lead Plaintiff Opportunity

News provided by

Robbins Geller Rudman & Dowd LLP

07 Sep, 2016, 18:11 ET